PolyPid Receives Buy Rating and $11 Price Target: Analyst Sees 300%+ Upside Potential Ahead of Pivotal Phase 3 Data

H.C. Wainwright has initiated coverage of PolyPid Ltd. (NASDAQ: PYPD)* with a Buy rating and an $11 price target, representing potential upside of nearly 300% from current trading levels around $2.80 per share. The bullish outlook comes as the late-stage biotech company approaches a potentially transformative topline data readout from its pivotal Phase 3 SHIELD II trial expected by the end of second quarter of 2025.

Analyst Brandon Folkes believes the market is significantly undervaluing PolyPid’s lead product D-PLEX100 and assigns a lower probability of success than the data warrants. This cautious market approach creates what the analyst describes as a favorable risk/reward opportunity for investors positioning ahead of the upcoming catalyst.

PolyPid’s proprietary PLEX technology represents a potential breakthrough in surgical infection prevention. The company’s lead product, D-PLEX100, provides local and prolonged delivery of doxycycline directly at surgical sites for up to 30 days post-surgery, addressing a critical healthcare challenge. Surgical site infections affect millions of patients annually and create significant cost burdens for hospitals and surgical centers.

What makes PolyPid’s approach particularly compelling is the encouraging regulatory signals received recently. In December 2024, an independent Data Safety Monitoring Board reviewed unblinded efficacy data from the first 430 patients in the SHIELD II trial and recommended concluding the study at 800 patients—meaningfully lower than the potential maximum of 1,100 patients. The analyst interprets this recommendation as a potential positive indicator of efficacy signals in the trial.

The company has generated significant historical data supporting D-PLEX100’s effectiveness. While a previous pivotal trial was impacted by COVID-related reductions in infection rates, strong results in specific patient subgroups provided evidence that supports expectations for positive SHIELD II results.

The report identifies substantial market opportunity, with D-PLEX100 targeting 4.5 million abdominal surgeries at initial launch, representing a $6.8 billion addressable market based on projected pricing assumptions. PolyPid plans to partner for commercial activities, which should help drive uptake while allowing the company to operate efficiently.

Beyond the lead product, PolyPid’s PLEX platform holds significant potential for localized drug delivery across various clinical applications but receives no value in the current stock price. The versatile technology can be applied to small molecules, proteins, peptides, and nucleic acids, potentially unlocking substantial future value as the company advances additional programs.

At a $20 million enterprise value, the report highlights that the risk/reward proposition is favorable ahead of the SHIELD II data. If successful, D-PLEX100 could generate over $300 million in revenue, potentially driving upside beyond the $11 price target. The analyst applies an 80% probability of success in their valuation framework.

With critical Phase 3 data expected in Q2 2025, PolyPid stands at a potential inflection point. The upcoming readout could validate both the lead product and broader technology platform, potentially transforming the company’s position in surgical infection prevention and justifying the analyst’s bullish price target representing significant upside potential for investors.